Chromosome analysis was performed on samples from 20 Brazilian patients with breast cancer. All the samples were from untreated patients who presented the clinical symptoms for months or years before surgical intervention. Six cases showed axillary lymph node metastases. Clonal chromosome abnormalities were detected in all cases. The numerical alterations most frequently observed involved the loss of chromosomes X, 19, 20, and 22 followed by gain of chromosomes 9 and 8. Among the structural anomalies observed, there was preferential involvement of chromosomes 11, 6, I , 7, 3, and 12, supporting previous reports that these chromosomes may harbour genes of importance in the development of breast tumors. Two cases with a family history of breast cancer had in common total or partial trisomy 1.
Breast cancer is the most common neoplasm and the leading cause of cancer related deaths among women in most countries (PARKIN et al. 1984; BORING et al. 1992) . According to the American Cancer Society (1994), the incidence of breast cancer has risen steadily with a cumulative risk of 12.6%, or one in eight women by age 85 for a girl born in 1990.
The natural history of breast cancer varies greatly according to age at onset, clinical features, histopathological characteristics, and genetic context. Although the majority of cases appear to be sporadic, a family history of breast cancer is considered to be the main risk factor. BRCAI located on chromosome band 17q21 (MIKI et al. 1994) , and BRCA2 mapped on 13q12-13 (WOOSTER et al. 1994 ) are considered to be responsible for most cases of hereditary breast cancer. Somatic mutations involving these genes in sporadic breast cancer are rare FUTREAL et al. 1994; MIRAJVER et al. 1995) . However, recent reports have suggested role for BRCAI in nonhereditary breast cancer (FITZGERALD et al. 1996; LANGSTON et al. 1996; VAUGHN et al. 1996) .
One potential marker for the tumorigenesis process is the degree of genetic change in the tissue at risk. Cytogenetic investigation using chromosome banding is a screening methodology that permits the analysis of individual cells. This method permits the assessment of intratumoral heterogeneity (PANDIS et al. 1994 (PANDIS et al. , 1996 as well as the identification of specific breakpoints that may indicate the existence of other as yet unidentified breast cancer genes.
Although there are many reports on the cytogenetics of breast cancer, data about chromosome alterations in primary tumors are limited, and there is very little information on clinical-histopathological features correlated with specific chromosomal alterations (HAINSWORTH et al. 1992; ZAFRANI et al. 1992; PANDIS et al. 1993 PANDIS et al. , 1996 TRENT et al. 1993; STEINARSD~TTIR et al. 1995) .
The objective of the present study was to investigate the karyotypic patterns of twenty breast carcinomas from Brazilian patients to obtain information on the spectrum of chromosomal alterations and, when possible, to correlate the results with clinical-histopathological characteristics and information on family history.
MATERIALS AND METHODS
Twenty untreated primary breast carcinomas (1 5 infiltrating ductal, 1 infiltrating lobular, 1 infiltrating tubular, and 3 intraductal carcinomas) were evaluated cytogenetically after short-to-medium term in vitro culture. The tumor samples obtained from 19 female patients and 1 male patient were collected from the Hospital Nossa Senhora das GraCas de Curitiba, Curitiba, and from the Hospital Universitario Regional Norte do Parana, Londrina, state of Parana, South Brazil. The tumors were classified morphologically according to the recommendations of the World Health Organization (WHO) (SOBIN 1981). A fragment of tumor close to that taken for histologic examination was brought to the cytogenetics laboratory. The tumor tissue fragments for chromosome evaluation were sectioned after removal of fatty and necrotic areas. Chromosome preparation was performed according to a previously described protocol (CAVALLI et al. 1995) . Chromosome studies were conducted only on primary cultures. G-banding (SCHERES 1972) and cytogenetic analysis followed routine methods. A total of 7-33 metaphases were fully karyotyped, according to the number of mitoses obtained in each case. Chromosomes were identified and classified according to the nomenclature proposed by the International System for Human Cytogenetic Nomenclature (ISCN 1995) .
RESULTS
Cellular morphology showed growth of epithelial cells in early primary cultures. Metaphases were obtained from dividing epithelial cells in the early growth cycle to prevent the overgrowth of fibroblasts observed in older cultures. On average, 15-day old cell cultures with high mitotic activity of epithelial cells were prepared for cytogenetic investigation.
Clonal karyotypic alterations were observed in all cases analyzed. Numerical changes were more frequently observed, involving the loss of chromosomes X (10 cases), 19 (7 cases), 20 and 22 (5 cases), followed by the gain of chromosomes 9 (5 cases) and 8 (4 cases). Structural chromosome anomalies preferentially involved chromosomes 11 (6 cases), 6 (5 cases), 1 (4 cases), and 7 (3 cases) ( Fig. 1 and 2 ).
The presence of chromosome markers was detected in 40% of the tumors. Nonclonal changes (not shown) were detected in all specimens; some of them identical to the clonal abnormalities seen in other cases [e.g., del(6q), + 8 and del(l1p)l. Normal cells were detected in 19 cases at frequencies ranging from 12 to 66%.
The number of cells after G-banding analysis and the composite karyotype observed in each case are presented in Table 2 .
DISCUSSION
The breast tumor is structurally composed by epithelial cells, stroma elements and other cell types (PON- TEN et al. 1990 ). Interactions among these cellular types are essential for successful tumoral growth, although the nature of these intratumor cell interactions are still unknown. One major limitation in in vitro breast tumor research is that myoepithelial cells have a doubling time of 24 hours and normal epithelial cells have a doubling time of 48 hours, while the population of cancer cells may take one week or more to double (PETERSON and VAN DEURS 1987) . Thus, separation of tumor cells from nonmalignant epithelium after in vitro culture is still a problem. On this basis, the presence of karyotypically normal cells is expected and frequently observed in breast tumor cultures.
Another important aspect is whether the medium used or the time of growth in culture favors the overgrowth of specific near-diploid cell lines. Different tissue culture techniques using specific medium for mammary tumor cells have been recently developed (PANDIS et al. 1992; STEINARSD~TTIR et al. 1995) . Differences were detected in the karyotypic profile according to the cell culture method used. However, the chromosomes more frequently involved regardless of the methods used, were chromosomes 1, 6, 8, 1 1, 3, 7, 16, 17, and 18, which are reported in the majority of cytogenetic studies on breast tumors (TRENT 1985; HILL et al. 1987; DUTRILLAUX et al. 1990; HAINSWORTH and GARSON 1990; MITCHELL and SANTIBANEZ-KOREF 1990; BULLERDIEK et al. 1993; Lu et al. 1993; PANDIS et al. 1993 PANDIS et al. , 1995 THOMPSON et al. 1993; TRENT et al. 1993; ROHEN et al. 1995; STEINARSD~TTIR et al. 1995) . In the present study, we found the nonrandom involvement of the same chromosomes as described above in addition to abnormalities involving chromosomes X, 19, 20, and 22. The chromosome abnormalities observed are in agreement with the results reported in the literature. However, we cannot rule out the possibility that the time in culture and/or the method used favored the preferential growth of these cells in vitro.
Most authors consider that chromosome 1 is the most frequently altered in breast cancer, often showing monosomy 1 or lp, polysomies for l q and other rearrangements including deletions, amplifications and translocations on the two chromsome arms (BIECHE and LIDEREAU 1995) . In our study, we found total or partial trisomy 1 and deletion and translocation involving chromosome 1. All these patients had a histopathological diagnosis of infiltrating carcinoma, three of them ductal, one lobular and one tubular. Patient age was 41-43 years. In two of these cases there was a family/personal history of breast cancer (cases 4 and 20), and lymph node metastases were observed in one case (case 20). These clinical-histopathological features and the presence of abnormalities of chromosome 1 may be associated with tumor progression. HAINSWORTH et al. (1992) found a significant correlation between rearrangements on chromosome 1 and poor prognosis. Losses of short arm of chromosome 1 are interpreted as secondary anomalies acquired during clonal evolution (PANDIS et al. 1995) . Deletions on 6q were observed in four cases of infiltrating carcinomas (three of them ductal and one tubular) and in one case of intraductal carcinoma (case 17). This abnormality is frequently described in breast carcinomas (DUTRILLAUX et al. 1990; HAINSWORTH et al. 1991; Lu et al. 1993; PANDIS et al. 1993; THOMPSON et al. 1993) . TRENT et al. (1993) observed deletions in 6q in the analysis of 34 metastatic breast tumors and provided evidence for the first model of progression of karyotypic alterations from primary localized to metastatic breast carcinoma. According to this model, the first step towards the progression may be associated with the alteration of one or more genes that may be located on one of the chromosomes frequently altered in breast cancer (e.g., Ip or 6q), which in turn may lead to generalized chromosome instability. Recently, some reports on benign proliferative breast diseases revealed the presence of deletions involving 6q (FLETCHER et al. 1991; LEUSCHNER et al. 1994 ; DAL CIN et a]. 1996). Deletions in 6q in benign tumors and breast carcinomas suggest that this abnormality may affect genes involved in the initial stages of mammary tumorigenesis. Alternatively, at the molecular level, the region 6q21-25 can harbor more than one gene that may possibly contribute to different steps in human tumorigenesis considering the high frequency and breakpoint heterogeneity of this deletion in the different tumors (ref. in MITEL-MAN 1994) . Molecular studies of breast carcinomas (DEVILEE et al. 1992; NEGRINI et al. 1994; FUJII et al. 1996) and of other tumors (MILLIKIN et al. 1991; FOULKES et al. 1993 ) revealed the loss of heterozygosity in 6q. The findings of 6q deletions after cytogenetic and molecular analysis suggest that one or more putative tumor suppressor genes might exist at this site.
Trisomy of chromosome 8, detected in 4/15 invasive ductal carcinomas, has been found by other authors in studies on the same type of pathology (BULLERDIEK et al. 1993; ROHEN et al. 1995) . BULLERDIEK et al. (1993) reported trisomy 8 in 2 of 16 cases which presented lymph node involvement and were positive for estrogen and progesterone receptors. In our study, two of four cases with trisomy 8 presented lymph node involvement. In general, 8p is known to be a common site of homogeneously staining regions in breast tumors (DUTRILLAUX et al. 1990 ). At present, the pathogenetically relevant locus involved in these amplifications is unknown. Comparison of the clinical- histopathological data for patients with or without trisomy 8 may confirm the role of this alteration in the etiology of infiltrating carcinomas. Total or partial loss involving chromosome 11 is frequently described in breast tumors, with regions 1 lp15 and 1 lq23-24 being commonly involved (ref. MITELMAN 1994) . In our study, we found del(ll)(pl5) (case l), and del(1 l)(q23) (cases 1 and 2), del(ll)(q12q14) (cases 8 and 9), add (ll)(p15) (case 18), and monosomy 11 (case 12). FERTI-PASSAN- TONOPOULOU et al. (1991) detected deletions at these sites in 20130 cases of breast carcinomas and suggested that these abnormalities were associated with tumoral progression and were indicative of poor prognosis. Chromosome 11 has been shown to be the site of oncogenes H-RAS, ETS, and INT, mapped to llp15, llq13 and llq23, respectively; of the W T l gene on 1 Ip, of the MEN1 locus on 1 Iql3, and of the ataxia telangiectasia gene mapped to the 11q22-23 region. Loss of heterozygosity (LOH) on I l p has been correlated with low estrogen receptor protein and tumor size in invasive breast carcinoma, both of which are indicators of a poor prognosis (MACKAY et al. 1988) . LOH for llq23 either alone or in conjunction with LOH for llp15.5 in breast tumors was found to be highly predictive of an aggressive postmetastatic disease course with reduced survival (WIN-QVIST et al. 1995) . GUDMUNDSSON et al. (1995) investigated LOH on chromosome 11 and found an association with positive node status in the llp15.5 and llp13 regions, and LOH at llp15.5 and llq22-qter region was correlated with a high S-phase fraction. If these observations hold true in other cases, screening for deletions in I lpl5 or llq23 may be useful for identifying patients at high risk to develop aggressive disease.
Structural alterations involving chromosome 7 was found in three cases (cases 2, 9, and 10). The breakpoint regions involved in the deletions of this chromosome are coincident with the localization of the oncogene EGFR (mapped on 7pll-13) and the MET oncogene (mapped on 7q31). BIECHE et al. (1992) showed that patients whose breast cancer carried a deletion on chromosome band 7q31 had a significantly higher risk of relapse and of death, and had a shorter metastasis-free and overall survival than those whose tumors did not have such a deletion. It is interesting to note that case 2 presented structural alterations in chromosome 11 and 7, both changes being related to a poor prognosis. Trisomy 7 was observed in three other cases (cases 5, 12, and 17). A similar trisomy has been detected in other series of breast tumors and is accepted as a primary chromosome anomaly (PANDIS et al. 1995) .
Loss of chromosomes X, 19, 20, and 22 was found in all the histological types of breast tumors analyzed (except in the lobular type) in our study. Loss of chromosome X was the most frequent alteration detected in our cases. This abnormality and some others (e.g., +7, + 10) have been reported in various tumors, but it has been questioned whether they were derived from neoplastic cells (LINDSTROM et al. 1991; JOHANSSON et al. 1993; ROGATTO et al. 1994) . Recently, analysis of loss of heterozygosity and deletion mapping on the X chromosome in human breast tumors revealed a high frequency of small regionalised deletions defining a t least three regions independent: (a) distal portion of a pseudoautosoma1 region of Xp; (b) within the pseudoautosomal region close t o the pseudoautosomal boundary; and (c) distal Xq (LOUPART et al. 1995) . This study suggested the presence of suppressor genes involved in breast cancer at these sites.
Monosomies of chromosome 19 were described in metastatic breast tumors after short-term culture (7-22' days) (TRENT et al. 1993 
